A novel therapeutic approach for the treatment of Multiple Myeloma and Lymphoproliferative disorders with an Antisense Drug

HEALTH
ONCOLOGY

PRODUCTION OF TRUNCATED IMMUNOGLOBULINS TO INDUCE CELLULAR DEATH

Multiple Myeloma is a bone narrow disease characterized by the proliferation of a malignant B lymphocyte. This disease is still **incurable** despite the development of new therapeutic protocols including proteasome inhibitors and therapeutic antibodies.

Antisense oligonucleotides have been studied since several years for modulates genomic expression and in most cases restore the functionality of an abnormal protein. In the original therapeutic approach described here after, the antisense oligonucleotides-mediated **exon skipping strategy** aims to induce the production of aberrantly rearranged immunoglobulins which cause cellular death by **apoptosis**.



Exon Skipping strategy

Competitive Advantages

- **Antisense drug** in association with best in class treatments **improves** chemotherapy efficacy.
- **Exon skipping** is a new mechanism of action to treat multiple myeloma that meet one of the unmet needs for this disease.
- Exon skipping targets especially plasma cells and is expected to induce **less side effects** than usual chemotherapy.

Development Status

- *In vitro* POC on Multiple Myeloma cell lines and patients cells.
- *In vitro* POC for AL Amyloidosis (rare disease).
- *In vitro* validation of the synergic effect with existing Chemotherapy
- *In vivo* POC on going

Business Opportunities

- **New Adjuvant Treatment** for Multiple Myeloma and other lymphoproliferative disorders like AL Amyloidosis (rare disease).
- New therapeutic solution for **refractory Multiple Myeloma** patients.
- **First in class** treatment : Antisense oligonucleotide inducing exon skipping is a new therapeutic strategy for B cell line disorders
- Strategy could be adapted to all **B cell line disorders : allergies**

#Keywords

Multiple myeloma
Rare Disease
Antisens drug
Exon skipping
B cell line disorders

Research Team

UMR 7276 CRIBL - CNRS/UNILIM
Université de Limoges
Limoges, France
Dr. Laurent Delpy

Partnership

Licensing or co-development

Intellectual Property

FR3043914 granted
WO2017/089359 pending

SATT GRAND CENTRE | SOCIÉTÉ D'ACCÉLÉRATION DU TRANSFERT DE TECHNOLOGIE

Contact

Magali GRANGER
Business Developer
T.+33 (0)6 34 22 36 89
magali.granger@sattgc.com

SATT Grand Centre

CLERMONT-FERRAND | LA ROCHELLE | LIMOGES | ORLÉANS | POITIERS | TOURS

Head Office : 8, rue Pablo Picasso
63000 CLERMOND-FERRAND - FRANCE

www.sattgc.com